WO1990002186A1 - Production of bluetongue virus non-structural proteins using a baculovirus expression vector - Google Patents

Production of bluetongue virus non-structural proteins using a baculovirus expression vector Download PDF

Info

Publication number
WO1990002186A1
WO1990002186A1 PCT/GB1989/000939 GB8900939W WO9002186A1 WO 1990002186 A1 WO1990002186 A1 WO 1990002186A1 GB 8900939 W GB8900939 W GB 8900939W WO 9002186 A1 WO9002186 A1 WO 9002186A1
Authority
WO
WIPO (PCT)
Prior art keywords
btv
protein
polypeptide
cells
infected
Prior art date
Application number
PCT/GB1989/000939
Other languages
French (fr)
Inventor
Polly Roy
Original Assignee
Polly Roy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polly Roy filed Critical Polly Roy
Publication of WO1990002186A1 publication Critical patent/WO1990002186A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to a process for producing bluetongue virus proteins.
  • Bluetongue virus is the prototype virus of the Qvbi ⁇ iTus genus (Reoviridae family) . It is vectored to vertebrates by Culicoides species and causes disease in certain ruminants, notably sheep.
  • the genome of BTV consists of 10 unique double-stranded (ds) RNA molecules, each believed to code for a single polypeptide product. (Gorman et al. , 1981; Sanger and Mertens, 1983).
  • the ten dsRNA species are contained in an inner core structure that contains five types of proteins, two that are major (VP3 and VP7) and three that are minor components (VPl, VP4 and VP6) .
  • the core is surrounded by an outer capsid consisting of two major proteins, VP2 and VP5, to give a complete virion particle with a diameter of approximately 69 nm.
  • non-structural proteins In addition to the above-mentioned structural proteins, three non-structural proteins (NSI, NS2 and NS3) appear in BTV infected cells. Their function in the replication or morphogenesis of BTV is not known. Two viral specific entities, tubules and granular inclusion bodies, are routinely obserbed in BTV infected cells (Lecatsas, 1968) . These morphological structures are attached to the intermediate filament component of the cell's cytoskeleton (Eaton, B.T. et al. , 1988) and are presumed to be involved in the virus assembly process.
  • tubular structures are composed entirely of one type of polypeptide, namely the 64,000 Dalton (64 kD) NSI protein, which is the gene product of BTV dsRNA middle size segment No. 6 (M6) .
  • 64,000 Dalton (64 kD) NSI protein which is the gene product of BTV dsRNA middle size segment No. 6 (M6) .
  • M6 BTV dsRNA middle size segment No. 6
  • a process for producing a polypeptide comprising a bluetongue virus non-structural protein in antigenic form which comprises infecting susceptible insects or cultured insect cells with an expression vector having a DNA segment coding for said polypeptide.
  • An example of such a polypeptide is the NSI protein of bluetongue virus.
  • insects and cultured insect cells are capable of producing bluetongue virus non- structural proteins in morphological forms which resemble structures observed in bluetongue-virus infected mammalian, cells.
  • BTV-NSI when produced in accordance with the invention in insect cells has been found to "self-assemble" into tubules which are similar to tubules observed in bluetongue virus infected sheep cells.
  • the expression vectors used in the method of the invention may comprise a recombinant baculovirus having a DNA segment coding for a polypeptide comprising a bluetongue virus non-structural protein.
  • Such recombinant baculoviruses may include promoter systems native to naturally occurring baculoviruses, for example the so-called “polyhedrin” promoter, or they may include other promoter systems capable of directing expression of polypeptide in transformed insect or cultured insect cells.
  • Especially suitable cultured insect cells are those of Spodoptera f_vugipe ⁇ da.
  • antigenic form as used herein to refer to a protein is meant a protein which is capable of exhibiting an antigenic property of a native bluetongue virus protein, e.g. the capability of binding to an antibody to said protein.
  • BTV serotype 10 (BTV-10) NSI gene product using an expression system based on recombinant baculoviruses is illustrated by the following Example.
  • the expressed protein has been shown to be similar in size and antigenic properties to the authentic BTV NSI protein. It reacts with BTV ' antibody and forms numerous tubular structures in the cytoplasm of the infected insect cells. The tubular structures have been purified to homogeneity from infected cell extracts. Further the expressed polypeptide has been used to identify antibodies to five United States BTV serotypes in infected sheep sera, indicating the potential of the expressed protein as a group reactive antigen in the diagnosis of BTV infections.
  • Example the BTV-10 M6 gene product is expressed in an insect baculovirus expression vector derived from AcNV.
  • A. Viruses and cells United States prototype BTV-10 was plaque cloned using monolayers of BHK-21 cells. The viral dsRNA was purified as described by Yamaguchi et al. (1988) and the 10 individual RNA segments separated and isolated as described previously (Purdy et al. , 1984). AcNPV and recombinant baculovirus stocks were grown and assayed in confluent monolayers of S. fvugipe ⁇ da cells in medium containing 10 fetal calf serum according to the procedures described by Brown and Faulkner (1977) • Occasionally virus stocks were made using spinner cultures of these insect cells.
  • B DNA cloning of the BTV10-M6 RNA.
  • Polyadenylation of BTV-10 dsRNA and synthesis of cDNA copies of the polyadenylated M6 RNA using an oligo(dT) 1 _ 1 o primer were undertaken as described previously (Purdy et al. , 1984).
  • the RNA templates were removed by treatment with 0.5 M K0H and double-stranded DNA generated by self-annealing. The products were repaired using the Klenow large fragment of DNA polymerase, followed by 3' tailing with dC and annealing to Pstl-cut, dG-tailed, pBR322 plasmid DNA (Maniatis et al. , 1982).
  • RNA gel electrophoresis blotting and hybridization.
  • Purified BTV-10 RNA was resolved on an agarose gel, blotted onto a Genescreen membrane (New England Nuclear, Boston MA) and hybridized to nick- translated cloned DNA by procedures described previously (Purdy et al. , 1984).
  • Plasmid DNA manipulations were carried out following the procedures described by Maniatis and associates (Maniatis et al. , 1982) . Restriction enzymes, T4 DNA ligase and the Klenow large fragment of DNA polymerase, were purchased from New England Biolabs, Inc. (Beverly, MA) . Calf intestine alkaline phosphatase was obtained from Boehringer Mannheim (FGR) .
  • S. fvugipevda cells were transfected with mixtures of infectious AcNPV DNA and DNA obtained from plasmid pAcBTV 10-6. Recombinant viruses were obtained as described previously (Inumaru and Roy, 1987) . One of the derived recombinant viruses was designated AcBTV 10-6.
  • glycerol, 5% ⁇ -mercaptoethanol, 62.5 mM Tris-HCl, 0.01 bromophenol blue, pH 6.8) were added to each sample and the mixture heated at 100°C for 10 min.
  • Proteins were analysed by electrophoresis in a 10-30$ linear gradient polyacrylamide gel in the presence of SDS (SDS-PAGE) as described by Laemmli (1970) . After electrophoresis, the gel was stained with 0.25% Coomassie brilliant blue.
  • the membrane was soaked for 1 hr at room temperature in anti-rabbit IgG-goat IgG-alkaline phosphatase conjugate (Sigma Chemical Co.), also diluted in blocking buffer. After further washing with PBST, bound antibodies were detected by incubating using Fast BB salt and a-Naphthyl phosphate (Sigma Chemical Co.) as substrate.
  • PBST PBS
  • a solid phase indirect micro-ELISA was used to demonstrate the reactivity of recombinant AcBTV 10-6 antigen with various polyclonal BTV antisera.
  • S. fs gipexda cells infected 2 hr previously with recombinant AcBTV 10-6 virus (see above) were collected and subjected to freezing and thawing followed by low speed centrifugation to remove cellular debris.
  • the supernatant was diluted (1:10- to 1:10,000-fold) with sodium carbonate buffer (15 mM Na-CO-, 36 mM NaHC0_, pH 9-6)-
  • sodium carbonate buffer 15 mM Na-CO-, 36 mM NaHC0_, pH 9-6)
  • a 96-well polyvinylchloride microplate (Flow Laboratories) was coated overnight at 4xC with 50fl of the diluted antigen.
  • the plate was washed three times between each step of the following protocol by flooding the wells of the plate with PBST buffer.
  • the antigen-coated microplate was washed and blocked with blocking solution for 3 hr at room temperature.
  • BTV antisera were diluted (1:100- to 1:12,800-fold) in blocking solution and 50 ⁇ l of diluted sera were added to each well.
  • Cells were infected with the AcBTV 10-6 recombinant baculovirus and the infected cells harvested 4 or 5 days post-infection. The cells were recovered, washed twice with PBS and resuspended in 10 mM Tris-HCl (pH 7-4) and disrupted by sonication. The resulting cell extract was loaded oh a 10% to 50 (wt/v) sucrose gradient in TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.4) and centrifuged at 40,000 rpm for 3 hr using an SW4l rotor. After centrifugation, the gradient was fractionated and a portion of each fraction was subjected to gel electrophoresis. The peak fractions containing NSI protein were pooled and pelleted by centrifugation for 2 hr at 40,000 rpm. The pellet was resuspended in 10 mM Tris HC1 buffer (pH 7.4).
  • a plasmid (pBTV10-6) containing the complete BTV-10 M6 sequence was constructed from two overlapping clones as described above (Fig. 2) .
  • the restriction enzyme M ⁇ el was used to isolate the entire coding region of the M6 DNA (including 1 bases upstream from the ATG initiation codon and 59 bases downstream from the TAG stop codon) and the DNA used to prepare a recombinant baculovirus transfer vector.
  • the 60 kD protein was NSI
  • a sample of the AcBTV 10-6 infected cell extract was electrophoresed, transferred onto a Durapore membrane and subjected to Western analyses using anti-BTV-10 sera as described in Methods.
  • the 60 kD protein (lane c) was identified by the alkaline phosphatase conjugate detection procedure.
  • tubules of various lengths were evident. In cross-section, they exhibited a diameter of ca 60 nm. Many of the tubules appeared to contain ribosome-like particles (Fig. 5. R arrowheads). Both the structures and arrangement of the tubules were comparable to the tubular structures reported by others in BTV infected BHK-21 cells (Huismans and Els, 1979). As expected, polyhedra were only evident in the AcNPV infected cells (Fig. 5. P arrowheads).
  • Fibrous structures were observed both in AcNPV and in the recombinant virus infected cells (Fig. 5) • In the latter, the tubules appeared to be aligned along the edges of bundles of the fibrous material (Fig. 5c and d) . Both the tubules and the fiberous structures were randomly oriented with respect to one another. In some cells bundles of fibers were seen in both the nucleus and the cytoplasm (Fig. 5e, f) , with tubules mostly, but not exclusively associated with the cytoplasmic fibers. Fewer tubules were seen in the nuclei (Fig. f)• Whether these tubules were formed in the nucleus, or occurred there because the cell was in the terminal stage of infection, is not known.
  • Recombinant virus infected cell extracts were absorbed to microtiter plates (representing some 50 ng of NSI protein per well) and incubated with either polyclonal BTV-2, or BTV-10, or BTV-11, or BTV-13, or BTV-17 sheep antisera, or with normal sheep serum as a control.
  • the derived antigen-antibody complexes were detected by incubating with anti-sheep-alkaline phosphatase conjugates followed by the addition of an enzyme substrate.
  • Fig. 7 all five BTV antisera reacted with the recombinant antigen in proportion to the end point titer of the antisera. No reaction was detected with the normal sheep serum. No reactivity was obtained when each of the BTV antisera was tested with AcNPVinfected cell extracts.
  • NSI is the major viral protein synthesized in BTV-infected cells and is a major constituent of the tubules which are observed in such cells. (Huismans and Els, 1979). It has now unexpectedly been found that baculovirus expressed NSI protein also form tubules in insect cells. The two overlapping clones (#14 and 39) were used to construct a plasmid containing the complete gene (pBTV 10-6) . A recombinant baculovirus was prepared with the NSI gene sequences under the control of the AcNPV polyhedrin promoter. The data herein shows that the BTV NSI protein is expressed to a high level in insect cells infected with this recombinant baculovirus.
  • NSI, NS2 and NS3 can be used as group specific probes to detect the presence of bluetongue virus (all 24 serotypes); Ritter and Roy, 1988.
  • BTV 10 NSI antigen can be used to detect antibodies to the US strains (BTV-2, BTV-10, BTV-11, BTV-14 and BTV-17) ; Urakawa and Roy, 1988.
  • a culture of AcNPV-BTV-10 has been deposited at the European Collection of Animal Cell Cultures (ECACC) on 10th August 1989 under Accession No. 89081017.
  • Fig. 1 Strategy used to determine the sequences of cDNA clones of the BTV- 10 M6 gene. The distance and directions in which individual strands of two overlapping clones were sequenced are shown by the solid arrows. Restriction enzyme sites used are as follows: Ma, Mael; Hd, Hind l; R, HinfI; D, DdeI; Pv,PuuI; Ms, spI.
  • FIG. 2 Schematic diagram of the construction of the transfer vector pAcBTVlO-6.
  • a pBR332-based plasmid (pBTV 10-6) containing the entire coding region of the BTV-10 M6 DNA was constructed from two overlapping partial clones as described in Methods.
  • the complete clone (pBTV10-6) was used to construct the transfer vector (pAcBTVlO-6) as described in Methods.
  • the sequence of the 5' insertion site was determined by the method of Maxam and Gilbert (18) using a Hin ⁇ HL restriction fragment (BTV DNA residue #296).
  • Fig. 3 Hydropathic plot and distribution of cvsteine residues for the predicted M6 gene product of BTV-10.
  • the plot involves a span setting of 21 amino acids.
  • Fig.4 Expression of NSl protein bv recombinant baculoviruses derived from the pAcBTV10-6 transfer vector.
  • S. frugiperda cells were infected with recombinant (c) or wild type AcNPV (b). Proteins were recovered at 72 hr post-infection and an aliquot of each sample was resolved by gel electrophoresis. Uninfected cells were treated similarly (a). The resolved protein bands were either detected by staining with Coomassie brilliant blue (A), or blotted onto nitrocellulose membranes and detected immunolog ⁇ cally with a ti BTV-10 serum (B) as described in Methods. The positions of NSI and the AcNPV polyhedrin protein (P) are indicated. Molecular weights (in kD) are indicated on the left.
  • FIG. 5 Electron micrographs of NSl-derived tubules produced by S. frugiperda cells infected with recombinant viruses.
  • S. frugiperda cells infected with AcNPV (panel a), or a recombinant virus (panels b-f) were fixed with 2% glutaraldehyde 72 hr post-infection and processed for electron microscopy as described in Methods.
  • P polyhedrin
  • V virus particles
  • M mitochondria
  • R ribosomes
  • F fibrous structure
  • T tubules
  • N nuclear membrane.
  • FIG. 6 Three-dimensional arrangement of the tubules in the infected S. frugiperda cells.
  • A A series of representative virus (A-H) of the single arrays in a thin section of the tubules were photographed at 10° intervals of specimen tilt.
  • B A schematic three-dimensional interpretation of the structure are represented (a, b and c).
  • Fig. 7 Reaction of bluetongue antibodies to recombinant baculovirus derived antigen using indirect ELISA: Recombinant AcBTV 10-6 infected cell extracts were adsorbed to the solid phase and examined using 1:100 to 1:12800 dilutions of sheep anti-BTV-2 serum ( ⁇ e), or anti-BTV- 10 serum (o o), or anti-BTV-11 serum ( ⁇ A), or anti-BTV-13 serum ( ⁇ ⁇ ), or anti-BTV-17 serum (G ⁇ ), or with normal sheep serum (gg U).
  • Fig. 8 SDS-PAGE of purified NSI protein stained with Coomassie brilliant blue: AcBTV10-6 recombinant baculovirus infected cells were disrupted and tubules were recovered by sedimenting in sucrose gradient (10-50% w/v) centrifugation as described in Methods. The peak fractions containing NSl were pooled and subjected to SDS-PAGE analysis. The proteins recovered from unpurif ⁇ ed recombinant virus infected cells (1) are compared with NSl protein purified through sucrose gradient centrifugation (2). - /S

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Bluetongue virus non-structural proteins (particularly Bluetongue NSI protein) are expressed in insect cells.

Description

PRODUCTION OF BLUETONGUE VIRUS NON-STRUCTURAL PROTEINS USING A BACULOVIRUS EXPRESSION VECTOR
This invention relates to a process for producing bluetongue virus proteins.
Bluetongue virus (BTV) is the prototype virus of the QvbiυiTus genus (Reoviridae family) . It is vectored to vertebrates by Culicoides species and causes disease in certain ruminants, notably sheep.
■ The genome of BTV consists of 10 unique double-stranded (ds) RNA molecules, each believed to code for a single polypeptide product. (Gorman et al. , 1981; Sanger and Mertens, 1983). The ten dsRNA species are contained in an inner core structure that contains five types of proteins, two that are major (VP3 and VP7) and three that are minor components (VPl, VP4 and VP6) . The core is surrounded by an outer capsid consisting of two major proteins, VP2 and VP5, to give a complete virion particle with a diameter of approximately 69 nm. In a prior patent application (EP-88301348.4-2105) there is described the production of these BTV structural proteins, particularly VP2 and VP3, in insect cells using a baculovirus expression vector. VP2 is able to elicit neutralizing antibody and VP3 can elicit group-reactive antibody and therefore these antigens may be used for diagnosis of, and as a vaccine against, BTV infection.
In addition to the above-mentioned structural proteins, three non-structural proteins (NSI, NS2 and NS3) appear in BTV infected cells. Their function in the replication or morphogenesis of BTV is not known. Two viral specific entities, tubules and granular inclusion bodies, are routinely obserbed in BTV infected cells (Lecatsas, 1968) . These morphological structures are attached to the intermediate filament component of the cell's cytoskeleton (Eaton, B.T. et al. , 1988) and are presumed to be involved in the virus assembly process. It has been shown (Huismans and Els, 1979) that the tubular structures are composed entirely of one type of polypeptide, namely the 64,000 Dalton (64 kD) NSI protein, which is the gene product of BTV dsRNA middle size segment No. 6 (M6) . There is a need to be able to produce additional antigenically active bluetongue virus proteins by recombinant DNA technology so that antigens are available for the effective diagnosis of BTV infection and for the development of vaccines.
Following the successful expression of antigenically competant BTV structural proteins in insect cells outlined above, it has now surprisingly been found that expression systems based on insect cells can efficiently be used* to achieve expression of BTV non-structural proteins in antigenic form. Thus according to the present invention there is provided a process for producing a polypeptide comprising a bluetongue virus non-structural protein in antigenic form which comprises infecting susceptible insects or cultured insect cells with an expression vector having a DNA segment coding for said polypeptide. An example of such a polypeptide is the NSI protein of bluetongue virus.
Surprisingly it has been found that insects and cultured insect cells are capable of producing bluetongue virus non- structural proteins in morphological forms which resemble structures observed in bluetongue-virus infected mammalian, cells. Thus, for example, BTV-NSI, when produced in accordance with the invention in insect cells has been found to "self-assemble" into tubules which are similar to tubules observed in bluetongue virus infected sheep cells.
Especially suitable expression vectors are those based on baculov ruses. Thus for example the expression vectors used in the method of the invention may comprise a recombinant baculovirus having a DNA segment coding for a polypeptide comprising a bluetongue virus non-structural protein.
Such recombinant baculoviruses may include promoter systems native to naturally occurring baculoviruses, for example the so-called "polyhedrin" promoter, or they may include other promoter systems capable of directing expression of polypeptide in transformed insect or cultured insect cells.
Especially suitable cultured insect cells are those of Spodoptera f_vugipeτda.
By the term "antigenic form" as used herein to refer to a protein is meant a protein which is capable of exhibiting an antigenic property of a native bluetongue virus protein, e.g. the capability of binding to an antibody to said protein.
The expression and characterisation of the BTV serotype 10 (BTV-10) NSI gene product using an expression system based on recombinant baculoviruses is illustrated by the following Example. The expressed protein has been shown to be similar in size and antigenic properties to the authentic BTV NSI protein. It reacts with BTV' antibody and forms numerous tubular structures in the cytoplasm of the infected insect cells. The tubular structures have been purified to homogeneity from infected cell extracts. Further the expressed polypeptide has been used to identify antibodies to five United States BTV serotypes in infected sheep sera, indicating the potential of the expressed protein as a group reactive antigen in the diagnosis of BTV infections.
In the Example the BTV-10 M6 gene product is expressed in an insect baculovirus expression vector derived from AcNV.
Example - Expression of BTV NSI
A. Viruses and cells. United States prototype BTV-10 was plaque cloned using monolayers of BHK-21 cells. The viral dsRNA was purified as described by Yamaguchi et al. (1988) and the 10 individual RNA segments separated and isolated as described previously (Purdy et al. , 1984). AcNPV and recombinant baculovirus stocks were grown and assayed in confluent monolayers of S. fvugipeτda cells in medium containing 10 fetal calf serum according to the procedures described by Brown and Faulkner (1977) • Occasionally virus stocks were made using spinner cultures of these insect cells.
B. DNA cloning of the BTV10-M6 RNA. Polyadenylation of BTV-10 dsRNA and synthesis of cDNA copies of the polyadenylated M6 RNA using an oligo(dT)1 _1o primer were undertaken as described previously (Purdy et al. , 1984). The RNA templates were removed by treatment with 0.5 M K0H and double-stranded DNA generated by self-annealing. The products were repaired using the Klenow large fragment of DNA polymerase, followed by 3' tailing with dC and annealing to Pstl-cut, dG-tailed, pBR322 plasmid DNA (Maniatis et al. , 1982). After transformation, clones containing the viral sequences were recovered and screened by colony hybridization (Grunstein and Hogness, 1975)- Hinfl restriction patterns of recombinant plasmids were compared as described previously (Purdy et al. , 1984).
C. RNA gel electrophoresis, blotting and hybridization. Purified BTV-10 RNA was resolved on an agarose gel, blotted onto a Genescreen membrane (New England Nuclear, Boston MA) and hybridized to nick- translated cloned DNA by procedures described previously (Purdy et al. , 1984).
D. Sequencing of BTV M6 DNA clones. Sequencing was carried out end-labeled, strand-separated, restriction fragments of plasmid DNA containing the viral M6 DNA using the Maxam and Gilbert method (Maxam and Gilbert, I98O) .
E. DNA manipulations and construction of a complete BTV M6 gene.
Plasmid DNA manipulations were carried out following the procedures described by Maniatis and associates (Maniatis et al. , 1982) . Restriction enzymes, T4 DNA ligase and the Klenow large fragment of DNA polymerase, were purchased from New England Biolabs, Inc. (Beverly, MA) . Calf intestine alkaline phosphatase was obtained from Boehringer Mannheim (FGR) .
Two M6 DNA clones representing nucleotides 1-1100 (#14) and 7OO-I769 (#39) were sequenced as reported previously (15, see Fig. 1) . The construction of plasmid pBTV 10-6 representing the complete M6 DNA is illustrated in Fig. 2. Clone #14 was initially recloned in the opposite orientation into the Pstl site of pBR322. The derived clone (#14-9) was then digested with Pvul and a fragment of DNA containing M6 residues I-898 was recovered and dephosphorylated (Fig. 2) . A Puyl derived fragment was obtained from clone #39 containing M6 residues 899-1769- The two fragments were ligated together. After transformation of Escherichia coli MC1061 cells and the selection of drug-resistant colonies followed by colony hybridization screening (Grunstein and Hogness, 1975) using the nick-translated products of M6 DNA derived from clones #14 and #39. clone pBTV 10-6 was identified and confirmed by the appropriate restriction enzyme and sequence analyses to contain BTV-10 M6 residues I-I769.
F. Construction of a recombinant baculovirus transfer vector. A
1746 base-pair DNA fragment containing the entire coding region of the BTV-10 M6 DNA, was excised from plasmid pBTV 10-6 with Kael, repaired with the Klenow large fragment of DNA polymerase, then cloned into the BαmHI site of the baculovirus transfer vector pAcYMl (Matsuura et al. , 19δ7) • The derived recombinant transfer vector (designated pAcBTV 10-6, Fig. 2) was characterised by restriction enzyme and sequence analyses (Maxam and Gilbert, 198O) and was shown to have the viral insert in the correct orientation for expression directed by the AcNPV polyhedrin promoter.
G. Transfection and selection of recombinant viruses. To obtain recombinant viruses that would express the BTV M6 gene,
S. fvugipevda cells were transfected with mixtures of infectious AcNPV DNA and DNA obtained from plasmid pAcBTV 10-6. Recombinant viruses were obtained as described previously (Inumaru and Roy, 1987) . One of the derived recombinant viruses was designated AcBTV 10-6.
H. Analysis of infected cell polypeptides by polyacrylamide gel electrophoresis♦ S. fvugipevda cells in 35 πim tissue culture dishes were infected with viruses at a multiplicity of 10 PFU/cell and the cells incubated at 28°C for 3 days. At the end of the incubation period, cells were rinsed three times with phosphate buffered saline (PBS) and resuspended in 100 μl of 10 mM Tris-HCl buffer (pH 7.4). 50 μl of protein dissociation buffer (2.3 SDS, 10/1. glycerol, 5% β-mercaptoethanol, 62.5 mM Tris-HCl, 0.01 bromophenol blue, pH 6.8) were added to each sample and the mixture heated at 100°C for 10 min. Proteins were analysed by electrophoresis in a 10-30$ linear gradient polyacrylamide gel in the presence of SDS (SDS-PAGE) as described by Laemmli (1970) . After electrophoresis, the gel was stained with 0.25% Coomassie brilliant blue.
I. Timminoblotting analyses. After SDS-PAGE, cellular proteins were transferred electrophoretically for 3 hr at 0.8 mA/cm (Kyhse-Anderson, 1984) into a Durapore membrane (Millipore Corp.) using a semi-dry electroblotter (Sartoblot II Sartorius Corp). After transfer, the membrane was soaked overnight at 4xC in blocking buffer (5% skimmed milk, 0.05 Tween 20 in PBS, pH 7-4). The membrane was then treated for 2 hr with rabbit anti-BTV-10 serum diluted 1000-fold in blocking buffer. Following a second wash with 0.05% Tween-20 in PBS (PBST) , the membrane was soaked for 1 hr at room temperature in anti-rabbit IgG-goat IgG-alkaline phosphatase conjugate (Sigma Chemical Co.), also diluted in blocking buffer. After further washing with PBST, bound antibodies were detected by incubating using Fast BB salt and a-Naphthyl phosphate (Sigma Chemical Co.) as substrate.
J. Electron micrographs of infected cells. S. fvugipeτda cells were infected with recombinant baculoviruses at a multiplicity of 10 PFU/cell and incubated at 2δxC for 3 days. The cells were washed with PBS, fixed with glutaraldehyde and treated with osmic acid. Cell sections were observed in a JE0L electron microscope.
K. ELISA for the detection of antibody to BTV NSI polypeptide using recombinant baculovirus derived antigens. A solid phase indirect micro-ELISA was used to demonstrate the reactivity of recombinant AcBTV 10-6 antigen with various polyclonal BTV antisera. S. fs gipexda cells infected 2 hr previously with recombinant AcBTV 10-6 virus (see above) were collected and subjected to freezing and thawing followed by low speed centrifugation to remove cellular debris. The supernatant was diluted (1:10- to 1:10,000-fold) with sodium carbonate buffer (15 mM Na-CO-, 36 mM NaHC0_, pH 9-6)- A 96-well polyvinylchloride microplate (Flow Laboratories) was coated overnight at 4xC with 50fl of the diluted antigen. The plate was washed three times between each step of the following protocol by flooding the wells of the plate with PBST buffer. The antigen-coated microplate was washed and blocked with blocking solution for 3 hr at room temperature. BTV antisera were diluted (1:100- to 1:12,800-fold) in blocking solution and 50μl of diluted sera were added to each well. After 2 hr of incubation the plate was washed and 100 μl of a 1:1000 dilution of anti-sheep IgG-alkaline phosphatase conjugate (Sigma Chemicals) was added to each well followed by 2 hr incubation at 28°C. The substrate, p-nitrophenylphosphate (Sigma Chemicals) solution (0.1% w/v final concentration), was added for 30 min, or less. After suitable colour development at room temperature the reaction was stopped by addition of 0.3 M NaOH. The optical density was read using a multichannel spectrophotometer (Microelisa Autoreader, MR 58O, Dynatech Co.) at a wavelength of 405 nm.
L. Purification of tubular stuctures by gradient centrifugation.
Cells were infected with the AcBTV 10-6 recombinant baculovirus and the infected cells harvested 4 or 5 days post-infection. The cells were recovered, washed twice with PBS and resuspended in 10 mM Tris-HCl (pH 7-4) and disrupted by sonication. The resulting cell extract was loaded oh a 10% to 50 (wt/v) sucrose gradient in TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.4) and centrifuged at 40,000 rpm for 3 hr using an SW4l rotor. After centrifugation, the gradient was fractionated and a portion of each fraction was subjected to gel electrophoresis. The peak fractions containing NSI protein were pooled and pelleted by centrifugation for 2 hr at 40,000 rpm. The pellet was resuspended in 10 mM Tris HC1 buffer (pH 7.4).
The results achieved in the above Example is apparent from the following discussion.
1. Nucleotide sequence determination of the BTV-10 M6 DNA and its predicted gene product. The sequence of the cloned M6 gene was determined on strand separated, end-labeled, restriction DNA fragments obtained from two overlapping clones (#14 and #39) using the strategy shown in Fig. 1. The distance each DNA strand was sequenced is indicated by an arrow. The complete nucleotide sequence of these DNA clones has been reported elsewhere (Lee and Roy, 1987) • Approximately 90% of the gene was sequenced in both directions. Excluding the homopolymeric tails, the gene is 1769 nucleotides long with a single open reading frame beginning with an RNA AUG triplet at residues 35-37. This open reading frame terminates with a UAG translation termination codon at residues #1691-1693 (Lee and Roy, 1987) . Based on the sequence data, the BTV-10 M6 RNA codes for a primary gene product composed of 5 amino acids with an estimated size of 64,445 Daltons (Table- 1) and an overall net positive charge of +2 at neutral pH. The protein has 16 cysteine residues (3%) • The hydropathic profile of the protein (Fig. 3) indicates that it contains several regions of hydrophobic amino acids (regions above the central line) throughout the molecule, particularly in the carboxy terminal half.
2. Construction of baculovirus recombinants. A plasmid (pBTV10-6) containing the complete BTV-10 M6 sequence was constructed from two overlapping clones as described above (Fig. 2) . To remove unnecessary sequences (such as the homopolymeric tails, the restriction enzyme Mαel was used to isolate the entire coding region of the M6 DNA (including 1 bases upstream from the ATG initiation codon and 59 bases downstream from the TAG stop codon) and the DNA used to prepare a recombinant baculovirus transfer vector.
Previous studies have demonstrated that for many genes the highest baculovirus expression levels are obtained with the transfer vector pAcYMl (Emery and Bishop, 1987 Matsuura et al. , 1987; Schmaljohn et al. , 1988) . This vector contains the entire upstream sequence of the AcNPV polyhedrin gene, including the A of the initiating ATG codon. The coding sequences of the BTV-10 M6 DNA were therefore inserted into the transfer vector pAcYMl as described above (Fig. 2) . The derived recombinant (pAcBTV 10-6) was analysed by restriction endonuclease digestion and the junction sequences determined (Fig. 3)« S- fTugipe da cells were transfected with mixtures of AcNPV DNA and the plasmid DNA pAcBTV 10-6. Recombinant viruses (e.g., AcBTV 10-6) were identified by their polyhedrin- negative plaque phenotypes and plaque purified three times using monolayers of S. frugiperda cells. 3. Expression of bluetongue virus NSI protein. In order to demonstrate that BTV-10 NSI protein was synthesized in recombinant baculovirus infected cells, protein extracts were prepared from insect cells infected with the recombinant virus AcBTV 10-6 as described above. Extracts were also made from AcNPV- and mock-infected cells. A sample of each preparation was subjected to SDS-PAGE and the resolved proteins stained with Coomassie brilliant blue. As shown in Fig. 4A (lane c) , the recombinant virus synthesized a protein with a molecular size of ca 60 kD, in agreement with the estimated size of the BTV-10 NSI protein (see Table 1). Based on comparisons of stained gels containing known quantities of bovine serum albumin, the amount of this protein was estimated to be of the order of 1 mg per 2 x 10 infected cells, i.e., as high as the polyhedrin protein made in AcNPV infected cells (compare Fig. 4A, lanes b and c) .
In order to confirm that the 60 kD protein was NSI, a sample of the AcBTV 10-6 infected cell extract was electrophoresed, transferred onto a Durapore membrane and subjected to Western analyses using anti-BTV-10 sera as described in Methods. As shown in Fig. 4B, the 60 kD protein (lane c) was identified by the alkaline phosphatase conjugate detection procedure.
4. Electron microscope analysis of cells infected with recombinants that express the BTV NSI protein. It has been postulated that the NSI protein of BTV is the sole component of the tubular structures identified in BTV-infected cells (Huismans and Els, 1979). An examination was therefore undertaken of electron micrographs of S. fvugiperda cells infected with the AcBTV 10-6 recombinant virus, or with wild-type AcNPV. As shown in Fig. 5b and in contrast to AcNPV infected cells (Fig. 5a) , numerous tubular structures were evident only in the cytoplasm in the recombinant virus infected cells (Fig. 5. T arrowheads). In the thin section tubules of various lengths were evident. In cross-section, they exhibited a diameter of ca 60 nm. Many of the tubules appeared to contain ribosome-like particles (Fig. 5. R arrowheads). Both the structures and arrangement of the tubules were comparable to the tubular structures reported by others in BTV infected BHK-21 cells (Huismans and Els, 1979). As expected, polyhedra were only evident in the AcNPV infected cells (Fig. 5. P arrowheads).
Fibrous structures were observed both in AcNPV and in the recombinant virus infected cells (Fig. 5) • In the latter, the tubules appeared to be aligned along the edges of bundles of the fibrous material (Fig. 5c and d) . Both the tubules and the fiberous structures were randomly oriented with respect to one another. In some cells bundles of fibers were seen in both the nucleus and the cytoplasm (Fig. 5e, f) , with tubules mostly, but not exclusively associated with the cytoplasmic fibers. Fewer tubules were seen in the nuclei (Fig. f)• Whether these tubules were formed in the nucleus, or occurred there because the cell was in the terminal stage of infection, is not known.
In order to assess the possible three-dimensional arrangement of the tubules in the infected S. f_v gipeτda cells, single arrays in thin sections were examined in a Jeol electron microscope equipped with a tilting stage. A series of photographs was taken at 10° intervals of specimen tilt. It was apparent from Fig. 6A that the circular particles visualised in the lower left of the picture taken at a -40° tilt transformed to oblique particules at a -30° tilt and were progressively observed as longitudinal tubules at -10° to the +50° tilting stages. Similar transformations were observed for other arrays of tubules in the section (see Fig. 6A) . A schematic three-dimensional interpretation of the structures is provided in Fig. 6B.
5- ET.TSA assays using recombinant virus derived NSI to identify bluetongue antibodies. Since the NSI gene (M6) of BTV-10 has been shown to be highly conserved among 20 BTV serotypes (Huismans and Cloete, 1987; Ritter and Roy, 1988) , the question of whether the NSI protein produced by the recombinant baculovirus reacted with homologous and heterologous BTV antisera was investigated using an ELISA test. Recombinant virus infected cell extracts were absorbed to microtiter plates (representing some 50 ng of NSI protein per well) and incubated with either polyclonal BTV-2, or BTV-10, or BTV-11, or BTV-13, or BTV-17 sheep antisera, or with normal sheep serum as a control. The derived antigen-antibody complexes were detected by incubating with anti-sheep-alkaline phosphatase conjugates followed by the addition of an enzyme substrate. As shown in Fig. 7. all five BTV antisera reacted with the recombinant antigen in proportion to the end point titer of the antisera. No reaction was detected with the normal sheep serum. No reactivity was obtained when each of the BTV antisera was tested with AcNPVinfected cell extracts.
6. Purified tubules recovered from recombinant virus infected insect cells. In order to purify the tubular structures, infected cell extracts were prepared and subjected to sucrose gradient centrifugation. A portion of each fraction was analysed by SDS-PAGE and peak fractions containing NSI protein were pooled and pelleted. As shown in Fig. 8, the recovered protein, stained with Coomassie brilliant blue, was effectively purified by this one-step procedure. Electron micrographs revealed that the preparation was composed of tubules with little evidence of cytoplasmic or other contamination.
SUMMARY
Two overlapping cDNA clones representing segment M6 of BTV-10 have been used to determine the complete sequence of the viral RNA. The sequence was deduced to be 1,769 base-pairs long, in good agreement with the 1.8 Kb length calculated by agarose gel electrophoresis. The single open reading frame of significant length is initiated with an AUG at residues 35"37 and codes for a protein of some 552 amino acids. The predicted NSI protein coded by the M6 RNA has a size of 64,445 Da. slightly larger than the size estimated by Huismans (1979). or- estimated the electrophoretic mobility of the protein observed in gels by comparison with protein markers (Fig. 4) . Computer analyses of the predicted amino acid sequences of the protein indicated that the molecule has domains of hydrophobic amino acids, particularly near the carboxy terminus, and contains many cysteine residues.
NSI is the major viral protein synthesized in BTV-infected cells and is a major constituent of the tubules which are observed in such cells. (Huismans and Els, 1979). It has now unexpectedly been found that baculovirus expressed NSI protein also form tubules in insect cells. The two overlapping clones (#14 and 39) were used to construct a plasmid containing the complete gene (pBTV 10-6) . A recombinant baculovirus was prepared with the NSI gene sequences under the control of the AcNPV polyhedrin promoter. The data herein shows that the BTV NSI protein is expressed to a high level in insect cells infected with this recombinant baculovirus. From stained preparation of cell extracts it was estimated that the amount of NSI present in cells infected at high multiplicity with the recombinant virus was ca 50% of the total stainable protein in the cell extract prepared at the end of the infection course. It has further been demonstrated that the recombinant baculovirus makes tubular structures in insect cells similar to those reported in BTV infected cell cultures (Huismans and Els, 1979). The tubules have been purified and demonstrated to be composed of NSI protein.
Previously it has been reported that the DNA probe representing the BTV M6 RNA hybridized with the corresponding RNA segments of 20 out of 20 BTV serotypes tested, indicating that the gene (and gene product) is highly conserved (Ritter and Roy, 1988) .
Moreover, unlike similar data obtained with genes representing the viral structural proteins, no hybridization was obtained with the corresponding segments of two epizootic haemorrhagic disease virus serotypes indicating that NSI genes are perhaps conserved only by BTV serotypes. If correct, then NSI antigen would be valuable as a reagent for the diagnosis of bluetongue virus infections. In order to investigate the value of the expressed NSI protein as a diagnostic reagent, recombinant virus derived NSI protein was applied in an ELISA test with five available US BTV antisera. The data obtained indicates that the genetically engineered NSI antigen is suitable for identifying all the US BTV serotypes.
The genes for NSI, NS2 and NS3 can be used as group specific probes to detect the presence of bluetongue virus (all 24 serotypes); Ritter and Roy, 1988.
BTV 10 NSI antigen can be used to detect antibodies to the US strains (BTV-2, BTV-10, BTV-11, BTV-14 and BTV-17) ; Urakawa and Roy, 1988.
DEPOSITS
A culture of AcNPV-BTV-10 (NSI) has been deposited at the European Collection of Animal Cell Cultures (ECACC) on 10th August 1989 under Accession No. 89081017.
LITERATURE CITED
1. Borden, E.C., R.E. Shope, and F.A. Murphy. 1971. Physicocheinical and morphological relationships of some arthropod-borne viruses to bluetongue virus - a new taxonomic group. Physico-chemical and serological studiesl J. Gen. Virol. 13:361-271.
2. Brown, M. and P. Faulkner. 1977. A plaque assay for nucler polyhedrosis viruses using a solid overlay. J. Gen. Virol. 36:361-364.
3. Eaton, B.T., A.D. Hyatt and J.R White. 1988. Localization of the nonstructural protein NSl . in bluetongue virus-infected cells and its presence in virus particles. Virology 163:527-537.
4. Emery, V.C. and D.H.L. Bishop. 1987. The development of multiple expression vectors for high level synthesis of eukaryotic proteins: expression of LCMV-N and AcNPV polyhedrin protein by a recombinant baculovirus. Protein Engineering 1 :359-366.
5. Grunstein, J.M. and D.S. Hogness. 1975. Colony hybridization: a method for the isolation of cloned DNAs that contain a specific gene. Proc. Natl. Acad. Sci. USA 72:3961-3965.
6. Huismans, H. 1979. Protein synthesis in bluetongue virus-infected cells. Virology 92:385-396.
7. Huismans, H. and M. Cloete. 1987. A comparison of different cloned bluetongue virus genome segments as probes for the detection of virus- specified RNA. Virology 15S.373-380. - -
8. Huismans, H. and H.J. Els. 1979. Characterization of the tubules associated with the replication of three different orbiviruses. Virology 92:387-406.
9. Inumaru, S. and P. Roy. 1987. Production and characterization of the neutralization antigen VP2 of bluetongue virus serotype 10. Virology 157:472-479.
10. Kyhse-Andersen, J. (1984). Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of protein from polyacrylamide to nitrocellulose. J. Biochem. and Biophys. methods 10:203-
11. Kyte, T. and R.F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105-132.
12. Laemmli, U.K. 1970. Cleavage of the structural proteins during assembly of the head of bacteriophage T4. Nature (London) 227:680-685.
13. Lecatsas, G. 1968. Electron microscope study of the formation of bluetongue virus. Onderstepoort J. Vet. Res.35:139-150.
14. Lecatsas, G. and B.M. Gorman. 1972. Visualization of the extra capsid coat in certain bluetongue-type viruses. Onderspoort J. Vet. Res. 39:193- 196.
15. Lee, J. and P. Roy, 1987. Complete sequence of the NSl gene (M6 RNA) of US bluetongue virus serotype 10. Nucleic Acids Research 15:7207.
16. Maniatis, T., E.F. Fritsche and J. Sambrook. 1982. Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Laboratory.
17. Matsuura, Y., R.D. Possee, H.A. Overton and D.H.L Bishop. 1987. Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins. J. Gen. Virol. 6S:1233-1250.
18. Maxam, A. and W. Gilbert. 1980. Sequencing end-labelled DNA with base-specific chemical cleavages. In L. Grossman and K. Moldave, (ed.)"Methods in Enzymology" Vol. 65, pp. 499-560. Academic Press, New York. 19. Purdy, M., Petre, J. and P. Roy. 1984. Cloning the bluetongue virus L3 gene. J. Virol. 51:754-759.
20. Ritter, D.G. and P. Roy. 1988. Genetic relationships of bluetongue virus serotypes isolated from different parts of the world. Virus Research 11: (in press).
21. Schmaljohn, C.S., K. Sugiyama, A.L. Schmaljohn and D.H.L. Bishop. 1988. Baculovirus expression of the small genome segment of Hantaan virus and potential use of the expressed nucleocapsid protein as a diagnostic antigen. J. gen. Virol. 69:777-786.
22. Yamaguchi, S., A. Fukusho and P. Roy. 1988. Complete sequence of neutralization protein VP2 of the recent US isolate bluetongue virus serotype 2: its relationship with VP2 species of other US serotypes. Virus Research 11: (in press).
23. Ritter, D.G. and P. Roy. 1988. Virus, Vol. 11, pages 33 to 47.
24. Urakawa and P. Roy. 1988. J. Virology, Vol. 62, pages 3919 to 3927.
FIGURE LEGENDS
Fig. 1 Strategy used to determine the sequences of cDNA clones of the BTV- 10 M6 gene. The distance and directions in which individual strands of two overlapping clones were sequenced are shown by the solid arrows. Restriction enzyme sites used are as follows: Ma, Mael; Hd, Hind l; R, HinfI; D, DdeI; Pv,PuuI; Ms, spI.
Fig. 2 Schematic diagram of the construction of the transfer vector pAcBTVlO-6. A pBR332-based plasmid (pBTV 10-6) containing the entire coding region of the BTV-10 M6 DNA was constructed from two overlapping partial clones as described in Methods. The complete clone (pBTV10-6) was used to construct the transfer vector (pAcBTVlO-6) as described in Methods. The sequence of the 5' insertion site was determined by the method of Maxam and Gilbert (18) using a HinάHL restriction fragment (BTV DNA residue #296).
Fig. 3 Hydropathic plot and distribution of cvsteine residues for the predicted M6 gene product of BTV-10. The regions of the protein that have a net hydrophobicity (areas above the center line), or hydrophilicity (areas below the center line), as well as the distribution of cvsteine residues (vertical bars), are displayed (11). The plot involves a span setting of 21 amino acids.
Fig.4 Expression of NSl protein bv recombinant baculoviruses derived from the pAcBTV10-6 transfer vector. S. frugiperda cells were infected with recombinant (c) or wild type AcNPV (b). Proteins were recovered at 72 hr post-infection and an aliquot of each sample was resolved by gel electrophoresis. Uninfected cells were treated similarly (a). The resolved protein bands were either detected by staining with Coomassie brilliant blue (A), or blotted onto nitrocellulose membranes and detected immunologϊcally with a ti BTV-10 serum (B) as described in Methods. The positions of NSI and the AcNPV polyhedrin protein (P) are indicated. Molecular weights (in kD) are indicated on the left.
Fig. 5 Electron micrographs of NSl-derived tubules produced by S. frugiperda cells infected with recombinant viruses. S. frugiperda cells infected with AcNPV (panel a), or a recombinant virus (panels b-f) were fixed with 2% glutaraldehyde 72 hr post-infection and processed for electron microscopy as described in Methods. P, polyhedrin; V, virus particles; M, mitochondria; R, ribosomes; F, fibrous structure; T, tubules; N, nuclear membrane.
Fig. 6 Three-dimensional arrangement of the tubules in the infected S. frugiperda cells. (A) A series of representative virus (A-H) of the single arrays in a thin section of the tubules were photographed at 10° intervals of specimen tilt. (B) A schematic three-dimensional interpretation of the structure are represented (a, b and c).
Fig. 7 Reaction of bluetongue antibodies to recombinant baculovirus derived antigen using indirect ELISA: Recombinant AcBTV 10-6 infected cell extracts were adsorbed to the solid phase and examined using 1:100 to 1:12800 dilutions of sheep anti-BTV-2 serum (β e), or anti-BTV- 10 serum (o o), or anti-BTV-11 serum (Δ A), or anti-BTV-13 serum (Δ Δ), or anti-BTV-17 serum (G □), or with normal sheep serum (gg U).
Fig. 8 SDS-PAGE of purified NSI protein stained with Coomassie brilliant blue: AcBTV10-6 recombinant baculovirus infected cells were disrupted and tubules were recovered by sedimenting in sucrose gradient (10-50% w/v) centrifugation as described in Methods. The peak fractions containing NSl were pooled and subjected to SDS-PAGE analysis. The proteins recovered from unpurifϊed recombinant virus infected cells (1) are compared with NSl protein purified through sucrose gradient centrifugation (2). - /S
Table 1. Amino acid composition of the predicted NSI protein of BTV-10
% of Mol. Ratio
7.4 77 5.7 3.6 2.9 7.0 4.7 5.9 2.5 7.0 7.6 4.2 4.2 4.7 3.6 4.5 4.2 2.3 5.1 4.9
Figure imgf000020_0001

Claims

- ή -
1. A process for producing a polypeptide comprising a bluetongue virus non-structural protein in antigenic form which comprises infecting susceptible insects or cultured insect cells with an expression vector having a DNA segment coding for said polypeptide.
2. A process according to Claim 1 wherein said DNA segment codes for bluetongue NSl protein.
3. A process according to* Claim 1 or Claim 2 wherein the polypeptide is produced in a morphological form resembling structures observed in bluetongue virus infected mammalian cells. . A process according to Claim 2 wherein said polypeptide is produced in the form of tubules.
5. A process according to any preceding claim wherein the expression vector comprises a recombinant baculovirus.
6. A recombinant baculovirus suitable for use in the process of any of Claims 1 to 5 comprising a DNA segment coding for a polypeptide comprising a bluetongue virus non-structural protein and a promoter capable of directing expression of said polypeptide in an infected insect or in infected insect cells.
7. A recombinant' baculovirus as claimed in Claim 6 wherein the promoter is the polyhedrin promoter.
8. A polypeptide produced by the process of any of Claims 1 to 5-
9. Use of a polypeptide as claimed in Claim 8 to diagnose bluetongue virus infection in mammals.
10. Use of a polypeptide as claimed in Claim 8 in the manufacture of a vaccine.
PCT/GB1989/000939 1988-08-16 1989-08-15 Production of bluetongue virus non-structural proteins using a baculovirus expression vector WO1990002186A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8819453.5 1988-08-16
GB888819453A GB8819453D0 (en) 1988-08-16 1988-08-16 Production of bluetongue virus non-structural proteins using baculovirus expression vector

Publications (1)

Publication Number Publication Date
WO1990002186A1 true WO1990002186A1 (en) 1990-03-08

Family

ID=10642209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1989/000939 WO1990002186A1 (en) 1988-08-16 1989-08-15 Production of bluetongue virus non-structural proteins using a baculovirus expression vector

Country Status (5)

Country Link
EP (1) EP0431038A1 (en)
AU (1) AU4198889A (en)
GB (1) GB8819453D0 (en)
WO (1) WO1990002186A1 (en)
ZA (1) ZA896202B (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026254A2 (en) * 2000-09-27 2002-04-04 The Uab Research Foundation Non-replicative particulate vaccine delivery system and methods of making and using same
WO2006069246A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
WO2009067636A2 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
WO2010037062A1 (en) 2008-09-26 2010-04-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
EP2284191A2 (en) 2004-12-22 2011-02-16 Ambrx, Inc. Process for the preparation of hGH
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
EP2327724A2 (en) 2004-02-02 2011-06-01 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178435A2 (en) * 1984-08-31 1986-04-23 Research Corporation cDNA probe for the detection of bluetongue virus
EP0279661A2 (en) * 1987-02-19 1988-08-24 Oxford Virology Limited Production of bluetongue virus antigens using a baculovirus expression vector

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178435A2 (en) * 1984-08-31 1986-04-23 Research Corporation cDNA probe for the detection of bluetongue virus
EP0279661A2 (en) * 1987-02-19 1988-08-24 Oxford Virology Limited Production of bluetongue virus antigens using a baculovirus expression vector

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biological Abstracts, Vol. 84, 1987, (Philadelphia, PA, US) H. HUISMANS et al.: "A Comparison of Different Cloned Bluetongue Virus Genome Segments as Probes for the Detection of Virus-Specified RNA" *see Abstracts 52328 & Virology, 158(2): 373-380, 1987* *
CHEMICAL ABSTRACTS, Vol. 106, No. 21, 25 May 1987, (Columbus, Ohio, US), S. INUMARU et al.: "Production and Characterization of the Neutralization Antigen VP2 of Bluetongue Virus Serotype 10 using a Baculovirus Expression Vector", see page 549* Abstract 174284t & Virology, 1987, 157(2), 472-9* *
J. Gen. Virol. , Vol. 67, 1986 SGM (GB) M.A. PURDY et al.: "Nucleotide Sequence of cDNA Clones Encoding the Outer Capsid Protein, VP5, of Bluetongue Virus Serotype 10", pages 957-962 *
J. Gen. Virol., Vol. 68, 1987, SGM (GB) S. INUMARU et al.: "Expression of Bluetongue Virus Group-Specific Antigen VP3 in Insect Cells by a Baculovirus Vector: its use for the Detection of Bluetongue Virus Antibodies" page 1627 *
Journal of Virology, Vol. 62, November 1988 American Soc. for Microbiology (US) T. URAKAWA et al.: "Bluetongue Virus Tubules made in Insect Cells by Recombinant Baculoviruses: Expression of the NS1 Gene of Bluetongue Virus Serotype 10" pages 3919-3927 *
Nucleic Acids Resaerch, Vol. 15, No. 17, 1987 IRL Press Ltd, Oxford, (GB) J. LEE et al.: "Complete Sequence of the NS1 Gene (M6 RNA) of Bluetongue Virus Serotype 10", page 7207 *

Cited By (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026254A3 (en) * 2000-09-27 2003-01-23 Uab Research Foundation Non-replicative particulate vaccine delivery system and methods of making and using same
WO2002026254A2 (en) * 2000-09-27 2002-04-04 The Uab Research Foundation Non-replicative particulate vaccine delivery system and methods of making and using same
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8097702B2 (en) 2004-02-02 2012-01-17 Ambrx, Inc. Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses
US9260472B2 (en) 2004-02-02 2016-02-16 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8907064B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8232371B2 (en) 2004-02-02 2012-07-31 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP2327724A2 (en) 2004-02-02 2011-06-01 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
EP2284191A2 (en) 2004-12-22 2011-02-16 Ambrx, Inc. Process for the preparation of hGH
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US7846689B2 (en) 2004-12-22 2010-12-07 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7858344B2 (en) 2004-12-22 2010-12-28 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7883866B2 (en) 2004-12-22 2011-02-08 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US8143216B2 (en) 2004-12-22 2012-03-27 Ambrx, Inc. Modified human growth hormone
US7829310B2 (en) 2004-12-22 2010-11-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
US7838265B2 (en) 2004-12-22 2010-11-23 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7959926B2 (en) 2004-12-22 2011-06-14 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone mutants
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US8178108B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US8163695B2 (en) 2004-12-22 2012-04-24 Ambrx Formulations of human growth hormone comprising a non-naturally encoded amino acid
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
EP2399893A2 (en) 2004-12-22 2011-12-28 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8178494B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Modified human growth hormone formulations with an increased serum half-life
WO2006069246A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US8053560B2 (en) 2006-09-08 2011-11-08 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US8022186B2 (en) 2006-09-08 2011-09-20 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US7919591B2 (en) 2006-09-08 2011-04-05 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8618257B2 (en) 2006-09-08 2013-12-31 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US9079971B2 (en) 2007-03-30 2015-07-14 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8383365B2 (en) 2007-03-30 2013-02-26 Ambrx, Inc. Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
US10377805B2 (en) 2007-03-30 2019-08-13 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
US9517273B2 (en) 2007-03-30 2016-12-13 Ambrx, Inc. Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US9975936B2 (en) 2007-03-30 2018-05-22 Ambrx, Inc. Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US11993637B2 (en) 2007-03-30 2024-05-28 Ambrx, Inc. Modified FGF-21 polypeptides with non-naturally encoded amino acids
US10961291B2 (en) 2007-03-30 2021-03-30 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
WO2009067636A2 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
EP3225248A1 (en) 2008-07-23 2017-10-04 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
US10428333B2 (en) 2008-09-26 2019-10-01 Ambrx Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US9156899B2 (en) 2008-09-26 2015-10-13 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US8569233B2 (en) 2008-09-26 2013-10-29 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
US9644014B2 (en) 2008-09-26 2017-05-09 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
EP3216800A1 (en) 2008-09-26 2017-09-13 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US9121025B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
WO2010037062A1 (en) 2008-09-26 2010-04-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US9962450B2 (en) 2010-08-17 2018-05-08 Ambrx, Inc. Method of treating heart failure with modified relaxin polypeptides
US9452222B2 (en) 2010-08-17 2016-09-27 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
EP4302783A2 (en) 2010-08-17 2024-01-10 Ambrx, Inc. Modified relaxin polypeptides and their uses
US11786578B2 (en) 2010-08-17 2023-10-17 Ambrx, Inc. Modified relaxin polypeptides and their uses
US10253083B2 (en) 2010-08-17 2019-04-09 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US11439710B2 (en) 2010-08-17 2022-09-13 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US11311605B2 (en) 2010-08-17 2022-04-26 Ambrx, Inc. Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
US8735539B2 (en) 2010-08-17 2014-05-27 Ambrx, Inc. Relaxin polypeptides comprising non-naturally encoded amino acids
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
US10702588B2 (en) 2010-08-17 2020-07-07 Ambrx, Inc. Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
US10751391B2 (en) 2010-08-17 2020-08-25 Ambrx, Inc. Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
US11248031B2 (en) 2014-10-24 2022-02-15 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US10377806B2 (en) 2014-10-24 2019-08-13 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
US10189883B2 (en) 2014-10-24 2019-01-29 Bristol-Myers Squibb Company Therapeutic uses of modified FGF-21 polypeptides
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US11185570B2 (en) 2017-02-08 2021-11-30 Bristol-Myers Squibb Company Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US11364281B2 (en) 2017-02-08 2022-06-21 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US12097242B2 (en) 2017-02-08 2024-09-24 Bristol-Myers Squibb Company Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides
US12097241B2 (en) 2017-02-08 2024-09-24 Bristol-Myers Squibb Company Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides

Also Published As

Publication number Publication date
AU4198889A (en) 1990-03-23
GB8819453D0 (en) 1988-09-21
EP0431038A1 (en) 1991-06-12
ZA896202B (en) 1990-08-29

Similar Documents

Publication Publication Date Title
WO1990002186A1 (en) Production of bluetongue virus non-structural proteins using a baculovirus expression vector
Urakawa et al. Bluetongue virus tubules made in insect cells by recombinant baculoviruses: expression of the NS1 gene of bluetongue virus serotype 10
Belyaev et al. Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells
French et al. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV
DE3751092T2 (en) Production and immunogenicity of rotavirus genes using a baculovirus expression system.
DE69223939T2 (en) METHOD FOR PRODUCING SUB-UNIT VACCINE AGAINST DOG PARVOVIRUS AND RELATED VIRUSES
Roy et al. Identification of bluetongue virus VP6 protein as a nucleic acid-binding protein and the localization of VP6 in virus-infected vertebrate cells
Le Blois et al. Synthesis and characterization of chimeric particles between epizootic hemorrhagic disease virus and bluetongue virus: functional domains are conserved on the VP3 protein
DE69019359T2 (en) HUMAN PARVOVIRUS B19 PROTEINS AND VIRUS-LIKE PARTICLES, THEIR PRODUCTION AND THEIR USE IN DIAGNOSTIC TESTS AND VACCINES.
JPH05292976A (en) Mareks' disease virus vaccine
JPH0365191A (en) Spheroidine isolated dna and recombinant insect pox virus expression vector
AP114A (en) Production of bluetongue virus antigens using a baculovirus expression vector.
Taylor et al. Transient expression and mutational analysis of the rotavirus intracellular receptor: the C-terminal methionine residue is essential for ligand binding
DE3382718T2 (en) Peptides containing an immunogen location of the Sabin strain poliovirus.
KR100224331B1 (en) Recombinant varicella-zoster virus and process for constructing same
US6379885B1 (en) Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines
EP0284791B1 (en) DNA and RNA molecules of the western-subtype TBE virus, polypeptides coded by these molecules and their use
JPH02501114A (en) Expression vectors for protein synthesis and plasmid replicons and sequence cassettes used in such vector construction
Monastyrskaya et al. Characterization and modification of the carboxy-terminal sequences of bluetongue virus type 10 NS1 protein in relation to tubule formation and location of an antigenic epitope in the vicinity of the carboxy terminus of the protein
AU667796B2 (en) Production of antigens by self-assembly of polypeptide components
US5686270A (en) Production of antigens by self-assembly of polypeptide components
Nel et al. A comparison of different cloned genome segments of epizootic haemorrhagic disease virus as serogroup-specific probes
Brun et al. The relationship of Piry virus to other vesiculoviruses: a re-evaluation based on the glycoprotein gene sequence
US5833995A (en) Use of bluetongue virus proteins as vaccine components
TANAKA et al. Synthesis of bluetongue virus chimeric VP3 molecules and their interactions with VP7 protein to assemble into virus core-like particles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989909839

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989909839

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989909839

Country of ref document: EP